Literature DB >> 15096184

Major histocompatibility complex class I-restricted alloreactive CD4+ T cells.

Louise H Boyle1, Jane C Goodall, J S Hill Gaston.   

Abstract

Although it is well established that CD4+ T cells generally recognize major histocompatibility complex (MHC) class II molecules, MHC class I-reactive CD4+ T cells have occasionally been reported. Here we describe the isolation and characterization of six MHC class I-reactive CD4+ T-cell lines, obtained by co-culture of CD4+ peripheral blood T cells with the MHC class II-negative, transporter associated with antigen processing (TAP)-negative cell line, T2, transfected with human leucocyte antigen (HLA)-B27. Responses were inhibited by the MHC class I-specific monoclonal antibody (mAb), W6/32, demonstrating the direct recognition of MHC class I molecules. In four cases, the restriction element was positively identified as HLA-A2, as responses by these clones were completely inhibited by MA2.1, an HLA-A2-specific mAb. Interestingly, three of the CD4+ T-cell lines only responded to cells expressing HLA-B27, irrespective of their restricting allele, implicating HLA-B27 as a possible source of peptides presented by the stimulatory MHC class I alleles. In addition, these CD4+ MHC class I alloreactive T-cell lines could recognize TAP-deficient cells and therefore may have particular clinical relevance to situations where the expression of TAP molecules is decreased, such as viral infection and transformation of cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15096184      PMCID: PMC1782457          DOI: 10.1111/j.1365-2567.2004.01857.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  54 in total

1.  Cytotoxic T-cell clone against rectal carcinoma induced by stimulation of a patient's peripheral blood mononuclear cells with autologous cultured tumor cells.

Authors:  L Jacob; R Somasundaram; W Smith; D Monos; S Basak; F Marincola; S Pereira; D Herlyn
Journal:  Int J Cancer       Date:  1997-05-02       Impact factor: 7.396

2.  The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation.

Authors:  P J Lehner; J T Karttunen; G W Wilkinson; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

Review 3.  TAP off--tumors on.

Authors:  B Seliger; M J Maeurer; S Ferrone
Journal:  Immunol Today       Date:  1997-06

Review 4.  Presentation of HLA class I-derived peptides: potential involvement in allorecognition and HLA-B27-associated arthritis.

Authors:  P Parham
Journal:  Immunol Rev       Date:  1996-12       Impact factor: 12.988

5.  The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP.

Authors:  K Ahn; A Gruhler; B Galocha; T R Jones; E J Wiertz; H L Ploegh; P A Peterson; Y Yang; K Früh
Journal:  Immunity       Date:  1997-05       Impact factor: 31.745

6.  A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter.

Authors:  H Hengel; J O Koopmann; T Flohr; W Muranyi; E Goulmy; G J Hämmerling; U H Koszinowski; F Momburg
Journal:  Immunity       Date:  1997-05       Impact factor: 31.745

7.  Cellular mechanisms involved in protection against influenza virus infection in transgenic mice expressing a TCR receptor specific for class II hemagglutinin peptide in CD4+ and CD8+ T cells.

Authors:  A Bot; S Casares; S Bot; H von Boehmer; C Bona
Journal:  J Immunol       Date:  1998-05-01       Impact factor: 5.422

8.  Human gamma delta T-cell recognition of Yersinia enterocolitica.

Authors:  J L Young; J C Goodall; H Beacock-Sharp; J S Gaston
Journal:  Immunology       Date:  1997-08       Impact factor: 7.397

9.  A single nonamer from the Yersinia 60-kDa heat shock protein is the target of HLA-B27-restricted CTL response in Yersinia-induced reactive arthritis.

Authors:  S Ugrinovic; A Mertz; P Wu; J Braun; J Sieper
Journal:  J Immunol       Date:  1997-12-01       Impact factor: 5.422

10.  Quantitative contribution of CD4 and CD8 to T cell antigen receptor serial triggering.

Authors:  A Viola; M Salio; L Tuosto; S Linkert; O Acuto; A Lanzavecchia
Journal:  J Exp Med       Date:  1997-11-17       Impact factor: 14.307

View more
  7 in total

1.  Genetic susceptibility to type 1 diabetes in the intracellular pathway of antigen processing - a subject review and cross-study comparison.

Authors:  Charles Sia; Michael Weinem
Journal:  Rev Diabet Stud       Date:  2005-05-10

2.  The role of HLA class I gene variation in autoimmune diabetes.

Authors:  Charles Sia; Michael Weinem
Journal:  Rev Diabet Stud       Date:  2005-08-10

Review 3.  HLA-B27 misfolding and spondyloarthropathies.

Authors:  Robert A Colbert; Monica L DeLay; Gerlinde Layh-Schmitt; Dawn P Sowders
Journal:  Prion       Date:  2009-01-03       Impact factor: 3.931

4.  Discovery of immunodominant T-cell epitopes reveals penton protein as a second immunodominant target in human adenovirus infection.

Authors:  Sabine Tischer; René Geyeregger; Julian Kwoczek; Albert Heim; Constanca Figueiredo; Rainer Blasczyk; Britta Maecker-Kolhoff; Britta Eiz-Vesper
Journal:  J Transl Med       Date:  2016-10-07       Impact factor: 5.531

5.  Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented EBV-derived T-cell epitopes.

Authors:  Maren Bieling; Sabine Tischer; Ulrich Kalinke; Rainer Blasczyk; Søren Buus; Britta Maecker-Kolhoff; Britta Eiz-Vesper
Journal:  Oncotarget       Date:  2017-12-21

6.  MHC Class I-Restricted TCR-Transgenic CD4+ T Cells Against STEAP1 Mediate Local Tumor Control of Ewing Sarcoma In Vivo.

Authors:  Sebastian J Schober; Melanie Thiede; Hendrik Gassmann; Carolin Prexler; Busheng Xue; David Schirmer; Dirk Wohlleber; Stefanie Stein; Thomas G P Grünewald; Dirk H Busch; Guenther H S Richter; Stefan E G Burdach; Uwe Thiel
Journal:  Cells       Date:  2020-06-29       Impact factor: 6.600

7.  Immunogenic SARS-CoV-2 Epitopes: In Silico Study Towards Better Understanding of COVID-19 Disease-Paving the Way for Vaccine Development.

Authors:  Vipin Ranga; Erik Niemelä; Mahlet Z Tamirat; John E Eriksson; Tomi T Airenne; Mark S Johnson
Journal:  Vaccines (Basel)       Date:  2020-07-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.